November 11, 2021
Nippon Shinyaku is getting its hands on French biotech Dynacure’s investigational antisense oligonucleotide being developed for centronuclear myopathies (CNM), with an option pact signed on November 10 for its development and commercialization in Japan. The two companies said in separate...read more